Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D.
Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D.
复制标题
原发性胆汁性肝硬化中的骨病：口服 25-羟基维生素 D 逆转骨软化症。
DOI：
10.1016/0016-5085(80)90865-3
复制
发表时间：
1980
期刊：
影响因子：
29.4
通讯作者：
J. Boyer
中科院分区：
文献类型：
--
作者：
J. S. Reed;S. Meredith;B. Nemchausky;I. Rosenberg;J. Boyer
对7例原发性胆汁性肝硬化女性患者的未脱钙髂嵴骨活检进行组织形态计量学分析，评估骨疾病和对口服25-羟基维生素D的反应。口服25-羟基维生素D治疗（每日100-200 μg）后，25-羟基维生素D的低血清浓度从9.2 ± 6.7（SD）升高至151.0 ± 103.7 ng/ml。初次活检时，7例患者中有5例出现骨软化。6例患者在持续治疗6-8个月后重复骨活检显示骨矿化显著改善，反映在类骨质表面分数和相对类骨质体积上。4例骨软化愈合，1例改善，1例仍无骨软化。7名患者中有6名的松质骨体积（矿化骨量的指标）减少，在6-8个月的治疗期间没有显著变化。我们的结论是，口服25-羟基维生素D纠正维生素D缺乏症和逆转原发性胆汁性肝硬化的骨软化。
Bone disease and the response to oral 25-hydroxyvitamin D were assessed in 7 women with primary biliary cirrhosis utilizing histomorphometric analysis of undecalcified iliac crest bone biopsies. Low serum concentrations of 25-hydroxyvitamin D rose from 9.2 ± 6.7 (SD) to 151.0 ± 103.7 ng/ml on oral 25-hydroxyvitamin D therapy (100–200 μg daily). On initial biopsy 5 of 7 patients had osteomalacia. Repeat bone biopsy in 6 patients after 6–8 mo of continued therapy revealed significant improvement in bone mineralization as reflected in fractional osteoid surface and relative osteoid volume. Osteomalacia healed in 4, improved in 1, and remained absent in 1. Trabecular bone volume, an index of mineralized bone mass, was diminished in 6 of 7 patients and did not change significantly over the 6–8-mo treatment period. We conclude that oral 25-hydroxyvitamin D corrects vitamin D deficiency and reverses osteomalacia in primary biliary cirrhosis.